Colleen F. Reitan net worth and biography

Colleen Reitan Biography and Net Worth

Former President of Plan Operations and Chief Operating Officer of Health Care Service Corporation; former President and Chief Operating Officer of Blue Cross Blue Shield of Minnesota; Director of Myriad Genetics.

What is Colleen F. Reitan's net worth?: The estimated net worth of Colleen F. Reitan is at least $360.64 thousand as of September 9th, 2025. Ms. Reitan owns 775 shares of Alnylam Pharmaceuticals stock worth more than $360,639 as of December 5th. This net worth evaluation does not reflect any other investments that Ms. Reitan may own. Learn More about Colleen F. Reitan's net worth.
How do I contact Colleen F. Reitan?: The corporate mailing address for Ms. Reitan and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]. Learn More on Colleen F. Reitan's contact information.
Has Colleen F. Reitan been buying or selling shares of Alnylam Pharmaceuticals?: Colleen F. Reitan has not been actively trading shares of Alnylam Pharmaceuticals during the past quarter. Most recently, Colleen F. Reitan sold 18,000 shares of the business's stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a transaction totalling $8,416,800.00. Following the completion of the sale, the director now directly owns 775 shares of the company's stock, valued at $362,390. Learn More on Colleen F. Reitan's trading history.
Who are Alnylam Pharmaceuticals' active insiders?: Alnylam Pharmaceuticals' insider roster includes Dennis Ausiello (Director), Michael Bonney (Director), Jeffrey Dunn (CEO), Kevin Fitzgerald (EVP), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), David Pyott (Director), Colleen Reitan (Director), Amy Schulman (Director), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Alnylam Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 29 times. They sold a total of 259,845 shares worth more than $97,190,879.32. The most recent insider tranaction occured on November, 17th when EVP Kevin Joseph Fitzgerald sold 12,128 shares worth more than $5,484,039.04. Insiders at Alnylam Pharmaceuticals own 1.5% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.
Information on this page was last updated on 11/17/2025.

Colleen F. Reitan Insider Trading History at Alnylam Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/9/2025	Sell	18,000	$467.60	$8,416,800.00	775

Colleen F. Reitan Buying and Selling Activity at Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $465.34

$463.03

$477.06

50 Day Range

MA: $456.55

$423.47

$491.22

2 Week Range

Now: $465.34

$205.87

$495.55

Volume

983,973 shs

Average Volume

907,941 shs

Market Capitalization

$61.48 billion

P/E Ratio

1,938.92

Dividend Yield

N/A

Beta

0.3